Stacks
Tesamorelin/Ipamorelin
Tesamorelin + Ipamorelin
Scientific Overview
Tesamorelin/Ipamorelin is a two-peptide research stack: tesamorelin, a growth hormone–releasing hormone analog, plus ipamorelin, a growth-hormone secretagogue. Component papers are published separately more often than as a fixed combination. This page does not claim a single pivotal trial of the pair.
Mechanism focus: Tesamorelin is studied at the GHRH receptor. Ipamorelin is studied at the ghrelin receptor. Overlapping research interest is GH-axis pharmacology, with each ligand documented on its own.
Research Use Cases
- Combined GHRH-receptor and ghrelin-receptor models
- Growth-hormone axis co-stimulation studies
- Comparison with tesamorelin or ipamorelin alone
- Identity testing of two-peptide preparations
Use-Case Study Notations
- Case-study notation: tesamorelin reviews describe a GHRH analog with its own pharmacokinetic literature.
- Case-study notation: ipamorelin is a selective GH secretagogue and a different receptor class.
- Read the Tesamorelin and Ipamorelin pages for the single-compound identities.
Selected Studies (English, PubMed)
Five peer-reviewed sources indexed on PubMed for the component peptides. This page does not claim a pivotal trial of the fixed combination. Links open the PubMed record for verification.
- Tesamorelin — PubMed 31644039
- Tesamorelin — PubMed 21283099
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — PubMed 21668043
- Tesamorelin improves fat quality independent of changes in fat quantity — PubMed 33756511
- Ipamorelin, the first selective growth hormone secretagogue — PubMed 9849822
Related compounds
Research Use Only. This page is educational and intended for laboratory research context. Products are not for human consumption and are not intended to diagnose, treat, cure, or prevent any disease.